BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics

BioMarin Pharmaceutical Inc. (BMRN)

Today's Latest Price: $77.04 USD

1.09 (1.44%)

Updated Nov 23 4:00pm

Add BMRN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

BMRN Stock Summary

  • BMRN has a market capitalization of $13,787,178,209 -- more than approximately 86.76% of US stocks.
  • The price/operating cash flow metric for Biomarin Pharmaceutical Inc is higher than 95.51% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 71.7%, Biomarin Pharmaceutical Inc's debt growth rate surpasses 85.67% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Biomarin Pharmaceutical Inc, a group of peers worth examining would be CORT, TER, RDFN, STMP, and MOMO.
  • BMRN's SEC filings can be seen here. And to visit Biomarin Pharmaceutical Inc's official web site, go to

BMRN Stock Price Chart Interactive Chart >

Price chart for BMRN

BMRN Price/Volume Stats

Current price $77.04 52-week high $131.95
Prev. close $75.95 52-week low $68.25
Day low $76.27 Volume 1,027,771
Day high $77.40 Avg. volume 1,782,020
50-day MA $76.81 Dividend yield N/A
200-day MA $93.26 Market Cap 13.99B

BioMarin Pharmaceutical Inc. (BMRN) Company Bio

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.

BMRN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$77.04$21890.36 28722%

We started the process of determining a valid price forecast for Biomarin Pharmaceutical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biomarin Pharmaceutical Inc ranked in the 99th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. As for the metrics that stood out in our discounted cash flow analysis of Biomarin Pharmaceutical Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 0.25 years, is 4.87% -- higher than 97.54% of stocks in our DCF forecasting set.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.28% of the free cash flow producing stocks we're observing.
  • As a business, Biomarin Pharmaceutical Inc experienced a tax rate of about 102% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 93.88% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BMRN, try KMDA, NVAX, THC, VRTX, and GEN.

BMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream

Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the…

PR Newswire | October 2, 2020

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) Investors

LOS ANGELES--(BUSINESS WIRE)---- $BMRN #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020 (the “Class Period”). BioMarin investors have until November 24, 2020 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to participate. On A

Business Wire | October 2, 2020

BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: November 24, 2020

NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of…

PR Newswire | September 30, 2020

BIOMARIN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States Distric

Business Wire | September 30, 2020

Akero Continues Efruxifermin Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Akero Therapeutics to continue with Mid stage Efruxifermin trial Akero Therapeutics Inc. (AKRO) reported that the company has received a written guidance from the FDA, allowing the company to pursue a novel combined Phase 2b/3 study design for pivotal efruxifermin ((EFX)) trials in NASH patients. The proposed trial design entails...

Avisol Capital Partners on Seeking Alpha | September 29, 2020

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo -0.63%
3-mo 3.55%
6-mo -27.80%
1-year -0.94%
3-year -6.86%
5-year -19.80%
YTD -8.88%
2019 -0.70%
2018 -4.51%
2017 7.64%
2016 -20.92%
2015 15.88%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.937 seconds.